Key result
Reactivation of the fetal cardiac gene program is a reliable marker of cardiac hypertrophy and heart failure, regulated by transcription factors such as SRF, GATA4/5/6, NF-ATs, TEF, MEF-2, and NRSF.
Understanding the transcriptional regulation of fetal cardiac genes may lead to the discovery of new regulators and pathways involved in cardiac disease and remodeling.
No immediate change to clinical management of hypertrophy or HF; leaves open targeted research on fetal gene regulators.
Reactivation of the fetal cardiac gene program in adults is a reliable marker of cardiac hypertrophy and heart failure. Normally, genes within this group are expressed in the fetal ventricles during development, but are silent after birth. However, their expression is re-induced in the ventricular myocardium in response to various cardiovascular diseases, and potentially plays an important role in the pathological process of cardiac remodeling. Thus, analysis of the molecular mechanisms that govern the expression of fetal cardiac genes could lead to the discovery of transcriptional regulators and signaling pathways involved in both cardiac differentiation and cardiac disease. In this review we will summarize what is currently known about the transcriptional regulation of the fetal cardiac gene program.
No takes yet. Share an insight, caveat, or question.
Kuwahara et al. (2012) conducted a review in Cardiac hypertrophy and heart failure. Reactivation of the fetal cardiac gene program is a reliable marker of cardiac hypertrophy and heart failure, regulated by transcription factors such as SRF, GATA4/5/6, NF-ATs, TEF, MEF-2, and NRSF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: